ArticleHIV medicine2026
Screening for Trypanosoma cruzi infection (Chagas disease) in the Latin American population living with HIV in London.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThere are an estimated 2482 people born in Latin American countries receiving care for HIV in the United Kingdom. Although national guidance recommends screening for Trypanosoma cruzi infection (Chagas disease) in this population, there is no formal screening programme. The aim of this study was to investigate the sero-epidemiology of T. cruzi in Latin American people living with HIV in London, with a view to informing screening strategies.
methodsThis was a cross-sectional study, using serological screening for T. cruzi and questionnaires. Adults receiving HIV care in three London hospital outpatient clinics and who were born in one of the 21 Chagas-endemic countries of South America, Central America or Mexico were identified by searching electronic medical records for country of birth codes. Eligible participants were invited to undergo T. cruzi screening (a single recombinant immunoglobulin G (IgG)-enzyme-linked immunosorbent assay (ELISA)) during routine HIV outpatient appointments. Positive screening tests were confirmed with an immunofluorescence antibody test, with discordant results resolved by an adjudicating immunoblot.
resultsA total of 351 participants were recruited between June 2023 and March 2025, including 181 (52%) who were born in Brazil, 73 (21%) in Colombia, 19 (5%) in Ecuador, 16 (5%) in Argentina, 15 (4%) in Venezuela and 12 (3%) in Bolivia. Uptake of serological screening was high (97% when offered face to face). Four participants (1%) had a positive screening test, of whom one had confirmed T. cruzi infection (seroprevalence 0.3%, 95% CI 0.01-1.6%), and three were deemed false positive screening tests.
conclusionsWe report a low seroprevalence of T. cruzi infection in Latin American migrants in London living with HIV. Since the clinical consequences of untreated T. cruzi infection can be fatal, screening uptake is high, and individuals in non-endemic countries generally only need to be screened once, we recommend testing all Latin American people with HIV, especially women of reproductive age, those from high-prevalence countries and those with poor immune-virological control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.